NFL Player Teams With Biopharma Co. to Help SCD Patients
Source: Streetwise Reports  (6/17/22)
Shares of Global Blood Therapeutics Inc. traded 12% higher after the company reported it has teamed up with New York Jets running back Tevin Coleman and his family to promote education and to offer hope and support to families affected by sickle cell disease. More >

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30
  (6/16/22)
The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report. More >

Biotech Co. Advances 3 New Clinical Stage Assets
  (6/16/22)
Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report. More >

Investors Gain a Breath of Fresh Air From Ph. 3 CS Trial Results
Source: Streetwise Reports  (6/13/22)
Optinose Inc. shares traded 40% higher after the company reported positive top-line data from its Phase 3 ReOpen2 Trial of XHANCE for use in treating chronic sinusitis without nasal polyps. More >

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise
  (6/10/22)
Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models. More >

New Drug for Peanut Allergy in Toddlers Shown Safe and Effective
  (6/10/22)
The response rate to DBV Technologies SA's drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition. More >

Biotech Co.'s Shares Soar on Ph. 2 Hematology Trial Results
Source: Streetwise Reports  (6/10/22)
Cogent Biosciences Inc. shares traded 70% higher after the firm reported positive clinical data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), a severe hematologic disorder. More >

Good Chance FDA Will Greenlight Solution for Dry Eye Disease
  (6/9/22)
Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report. More >

Small Biomedical Device Co. Is Ready to Take a Big Step Into Success
Source: Tim Weintraut  (6/8/22)
After weathering some major setbacks, PetVivo Holdings Inc. is stepping it up. With their new product for osteoarthritis and the team's perseverance, they may soon show themselves as a diamond in the rough. More >

Biopharma Co. Meets Primary Endpoints in ARDS Trial
Source: Streetwise Reports  (6/8/22)
MediciNova Inc. shares traded 9% higher after the company released top-line data from its Phase 2 study of MN-166 (ibudilast) in hospitalized COVID-19 patients deemed to be at elevated risk for acute respiratory distress syndrome. In the study, MN-166 demonstrated significant decreases in respiratory failure. More >

FDA Approves Co.'s New Medical Grade Air Hygiene Device
Source: Streetwise Reports  (6/7/22)
Shares of AeroClean Technologies Inc. traded 150% higher after the company reported it received 510k clearance from the U.S. FDA for its Pūrgoâ„¢ medical-grade indoor air purification technology that uses UV-C LEDs to eradicate airborne bacteria, fungi, and viruses, including COVID-19. More >

Approved Drug Shows Promise in Follicular Lymphoma
  (6/6/22)
Comparison of new and previous clinical trial data shows improved efficacy, noted a Wedbush report. More >

FDA Approval of Drug Could Be on the Way
  (6/3/22)
"We continue to see good overall odds of ultimate approval" despite the current delay, noted an H.C. Wainwright & Co. report, regarding Verrica Pharmaceuticals topical drug for molluscum contagiosum, a viral skin infection. More >

Bristol Myers to Buy Precision Oncology Co.
Source: Streetwise Reports  (6/3/22)
Turning Point Therapeutics Inc. shares traded 116% higher after the company reported it entered into a definitive agreement to be acquired by Bristol Myers Squibb Co. in an all-cash transaction for $76.00 per share. More >

Precision Oncology Co. Signs $1.325B Licensing Deal
Source: Streetwise Reports  (6/2/22)
Repare Therapeutics Inc. shares traded more than 50% higher after the company reported it entered into a worldwide license and collaboration agreement with Roche AG for its anti-tumor drug camonsertib (RP-3500). The agreement includes an upfront payment of $125 million and up to an additional $1.2 billion in development, sales and royalties if certain milestones are achieved. More >

Important Data for COVID Drug Candidate Due This Month
  (6/2/22)
The "update should be important for determining EDP-235's potential to tap into this large market," noted a ROTH Capital Partners report. More >

Cancer Patients Have Partial Response With Drug
  (5/28/22)
The developer of this antibody just released the results of its dose evaluation in solid tumors, noted a Wedbush report. More >

Cancer Targeting Drug Better Tolerated Than Others
  (5/27/22)
A comparison of safety data shows this Phase 3 treatment candidate for liposarcoma differentiates itself from competitors with its superior safety profile, noted an Oppenheimer report. More >

50% Revenue Growth Expected This Year for Biopharma Co.
  (5/26/22)
The company is pursuing several strategies to boost revenue, including clinical trials to possibly expand the label of one of its approved dermatological drugs, noted a ROTH Capital Partners report. More >

Target Price on Drug Co. Suggests Possible Huge Returns
  (5/25/22)
Through H2/22, this biopharma intends to keep advancing its psychedelic drug formulations for major depression, noted a ROTH Capital Partners report. More >

US Biopharma Co. Chooses One Endpoint for Phase 3 Trial
Source: Dr. Thomas Shrader  (5/24/22)
With this strategic decision, the company hopes to increase the chances its dry eye disease drug gets greenlighted, noted a BTIG report. More >

Innoviva Buys Remaining Shares in Advanced Antibiotic Co.
Source: Streetwise Reports  (5/23/22)
Shares of Entasis Therapeutics traded 21% higher after the company reported it entered into a definitive merger agreement with Innoviva Inc., whereby Innoviva will acquire all outstanding shares of Entasis that it does not already own for $2.20 per share. More >

H2/22 Slated to Be Catalyst Rich for Pharma Co.
  (5/21/22)
Streetwise looks over the latest events surrounding Syros Pharmaceuticals after a Roth Capital Partners report shared that its newest updates could bolster the cash position of the firm and, thus, allow it to continue advancing all of its clinical programs. More >

US Pharma Co. Granted FDA Approval for IV Smallpox Drug
Source: Streetwise Reports  (5/20/22)
SIGA Technologies Inc. shares traded 30% higher after the company reported that the U.S. FDA has granted approval for an intravenous (IV) formulation of its TPOXX® (tecovirimat) for use in treating smallpox. More >

New Improved Drug Expected to Get FDA Approval Next Month
  (5/20/22)
Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock. More >